VANCOUVER, July 2, 2019 /CNW/ – Further to its press release of February 8, 2019, Zenabis Global Inc. ("Zenabis" or the "Company") (TSX:ZENA) is pleased to announce that it has signed a Commitment Letter (the "Commitment Letter") with the lender for its $25,000,000 credit facility (the "Facility") to amend and restate the secured debenture governing the terms thereof (the "Amendment").

Subject to receipt of all required regulatory approvals, the Amendment will extend the maturity date of the Facility from October 17, 2019 to the date that is one year from the date of the closing of the Amendment (the "Closing Date"). The Closing Date is expected to be on or around July 5, 2019. The terms of the Facility, including the interest rate and the financial covenants, will otherwise remain substantially the same, except that the prepayment penalty has been substantially reduced. In connection with the Amendment, subject to receipt of all required regulatory approvals, Zenabis will issue the lender $12,500,000 of common share purchase warrants (50% warrant coverage) entitling the lender to acquire one common share of the Company (each, a "Common Share") for a period of one year commencing on the Closing Date at the price that is a 15% premium to the closing price of the Common Shares on the TSX on the date before the Closing Date.

Andrew Grieve, Chief Executive Officer of Zenabis, remarked, "We appreciate the lender's continuing support as evidenced by its willingness to extend the credit facility under reasonable terms, including a significant reduction in the prepayment penalty, which limit dilution as much as possible. We believe this extension allows us to continue to invest in our business, rapidly increasing our production and revenues, leaving us in a preferred position to retire this debt next year. In addition, we continue to make progress on our goal of refinancing our existing debt into a single, consolidated facility."

About Zenabis

Zenabis is a significant Canadian licensed cannabis cultivator of medical and recreational cannabis, and a propagator and cultivator of floral and vegetable products. Zenabis employs staff coast-to-coast, across facilities in Atholville, New Brunswick; Delta, Aldergrove, Pitt Meadows and Langley, British Columbia; and Stellarton, Nova Scotia. In addition to gaining technologically advanced knowledge of plant propagation, the recent addition of state-of-the-art greenhouses in Langley, Pitt Meadows and Aldergrove provides Zenabis with 3.5 million square feet of facility space that can, if fully converted, be dedicated to cannabis production.

If all facility space at Zenabis Atholville, Zenabis Stellarton, Zenabis Delta and Zenabis Langley is fully converted and dedicated to production, Zenabis will own, and have access to 660,000 square feet of high quality indoor cannabis production space, as well as 2.1 million square feet of greenhouse cannabis production space at its Langley facility, with this production strategically positioned on Canada's coasts. Zenabis expects these facilities to have an annual design capacity of 131,200 kg of dried cannabis by the third quarter of 2019. These facilities, if fully built out and converted for cannabis production, would have an annual design capacity to yield approximately 478,800 kg of dried cannabis annually, for both national and international market distribution. An additional 700,000 square feet of greenhouse space will be used to continue the existing propagation business and produce industrial hemp, and can be converted to cannabis production at such a time that is beneficial to the strategic position of the Company. The Zenabis brand name is used in the cannabis medical market, while the Namaste and Blazery brand names are used in the cannabis adult-use recreational market, and the True Büch brand name is used for Zenabis' kombucha products.

"Forward Looking Information

This news release contains statements that may constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information may include, among others, statements regarding the future plans, costs, objectives or performance of Zenabis, or the assumptions underlying any of the foregoing. In this news release, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the receipt of all required regulatory approvals for the completion of the Amendment (including the issuance of common share purchase warrants to the lender), the completion and closing of the Amendment and the projected Closing Date of the Amendment.. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond Zenabis' control. These risks, uncertainties and assumptions include, but are not limited to, those described in the shelf prospectus dated April 9, 2019, a copy of which is available on SEDAR at www.sedar.com and could cause actual events or results to differ materially from those projected in any forward-looking statements. Furthermore, any forward-looking information with respect to available space for cannabis production is subject to the qualification that management of Zenabis may decide not to use all available space for cannabis production, and the assumptions that any construction or conversion would not be cost prohibitive, required permits will be obtained and the labour, materials and equipment necessary to complete such construction or conversion will be available. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Zenabis does not intend, nor undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events or circumstances or otherwise, except if required by applicable laws.

For more information, visit: https://www.zenabis.com.

SOURCE Zenabis Global Inc.

For further information: Media Relations: Email: [email protected], Phone: 1-844-523-8679; Investor Relations: E-mail: [email protected], Phone: 1-844-523-8679

Related Links

www.zenabis.com

